Information about Abbott Laboratories: PharmaVitae Profile

News-Press Release

(Newsbox) 18-Aug-2011

Bharatbook added a new Database "Abbott Laboratories: PharmaVitae Profile" provides data in PDF and SlidePack Format which contains information on Abbott which has utilized M&A to become one of the world's largest multi-disciplinary healthcare companies.

This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. ( http://www.bharatbook.com/detail.asp?id=70223&rt=Abbott-Laboratories-PharmaVitae-Profile.html )
 
 Features and benefits  - Gain insight into Abbott's strategic outlook across the next 6 years. Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.Highlights - Strategic insight into the prospects for Abbott over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
 
 Your key questions answered - Benchmark Abbott's performance against key rivals in the prescription pharmaceutical sector. Discover how Abbott has utilized M&A to become one of the world's largest multi-disciplinary healthcare companies.
 
 For more information kindly visit : http://www.bharatbook.com/detail.asp?id=70223&rt=Abbott-Laboratories-PharmaVitae-Profile.html
 
 Related Reports
 
 Starkey Laboratories, Inc. Market Share Analysis
 
 Cleveland Biolabs Inc-Detailed Product Pipeline
 
 -30-
 
 Or
 
 Contact us at :
 
 Bharat Book Bureau
 Tel: +91 22 27578668
 Fax: +91 22 27579131
 Email: info@bharatbook.com 
 Website: www.bharatbook.com 
 Follow us on twitter: http://twitter.com/#!/BharatBook

Contact Info

Tag Cloud

Categories

This release was submitted by a Newsbox user.  Any communication related to the content of this release should be sent to the release submitter.